Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

William Blair analysts on Monday raised their revenue and profit estimates for Nvidia over the next two fiscal years, citing ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.

Morgan Stanley's Keith Weiss took an unusual approach to backing away from his bearish stance on Tuesday, as he moved from an underweight call to a "not-rated" position in the wake of earnings.

William Blair analyst Louie DiPalma has maintained their bearish stance on PLTR stock, giving a Sell rating yesterday. Louie DiPalma has given ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Altair Engineering (NASDAQ:ALTR – Free Report) had its price target boosted by Royal Bank of Canada from $90.00 to $113.00 in ...

At 12:16 p.m. Tuesday, Donald Trump’s political director, James Blair, posted an alarming message on X — siren emoji and all ...

PayPal (PYPL.O) forecast fourth-quarter revenue below estimates earlier this week as the digital payments company shifts its ...

The payment company is connecting installment lenders with borrowers who may be looking for a product instead of a specific ...